Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EndoMAP: Targeted Agents and/or Atezolizumab in Recurrent or Persistent Endometrial Cancer
NCT04486352Phase 2Recruiting
- Sponsor
- Alliance Foundation Trials
- Start
- Oct 2021
- Primary completion
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab, ipatasertib, talazoparib, trastuzumab emtansine in endometrial cancer (EC), sponsored by Alliance Foundation Trials. Started Oct 2021; status: recruiting.
02
Drugs
atezolizumabbevacizumabipatasertibtalazoparibtrastuzumab emtansine
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04486352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486352.